Anavex Life Sciences Corp. (AVXL) Cash Flow Statement
Anavex Life Sciences Corp. (AVXL) generated -$29.3M of operating cash flow over the twelve months to 2026-06-30, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
AVXLAnavex Life Sciences Corp.Follow AVXL — free
—
Price chart with a free account
- Market cap
- 123.3M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 23 Nov, in 30 days
| Line | FY2006 Sep 06 | FY2007 Sep 07 | FY2008 Sep 08 | FY2009 Sep 09 | FY2010 Sep 10 | FY2011 Sep 11 | FY2012 Sep 12 | FY2013 Sep 13 | FY2014 Sep 14 | FY2015 Sep 15 | FY2016 Sep 16 | FY2017 Sep 17 | FY2018 Sep 18 | FY2019 Sep 19 | FY2020 Sep 20 | FY2021 Sep 21 | FY2022 Sep 22 | FY2023 Sep 23 | FY2024 Sep 24 | FY2025 Sep 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | — | — | — | — | — | -3.8 | -1.7 | -0.8 | -2.7 | -4.2 | -9.2 | -9.0 | -12.6 | -18.5 | -21.3 | -30.4 | -24.2 | -27.8 | -30.8 | -39.0 | -29.3 | |
| Capital expenditure | — | — | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | — | — | — | — | — | — | — | — | — | — | — | — | |
| Free cash flow | — | — | — | — | — | -3.8 | -1.7 | -0.8 | -2.7 | — | — | — | — | — | — | — | — | — | — | — | — | |
| Stock-based compensation | — | — | — | — | — | 1.3 | 0.3 | 1.0 | 0.6 | 1.6 | 5.1 | 4.1 | 5.5 | 6.4 | 4.9 | 8.2 | 18.4 | 16.4 | 9.4 | 11.5 | — |
USD millions · SEC XBRL
Anavex Life Sciences Corp. — questions
- What is Anavex Life Sciences Corp.'s operating cash flow?
- -$29.3M over the twelve months to 2026-06-30.
Every figure on this page comes from Anavex Life Sciences Corp.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.